Celldex Therapeutics, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021. Celldex is a clinical-stage biopharmaceutical company developing antibody therapeutics; it reported no product sales. Financial amounts below are in U.S. dollars.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Revenue | $0.7 million | $2.7 million; down 75% |
| Research and development expense | $12.7 million | $11.7 million; up 9% |
| General and administrative expense | $4.1 million | $3.7 million; up 12% |
| Total operating expenses | $17.3 million | $15.6 million; up 11% |
| Operating loss | $16.6 million | $12.9 million |
| Net loss | $16.5 million | $12.6 million; loss increased 31% |
| Basic and diluted loss per share | $0.42 | $0.73 |
| Net cash used in operations | $18.1 million | $12.1 million |
Revenue consisted of $0.003 million from product development and licensing agreements and $0.682 million from contracts and grants. The prior-year quarter included a $1.8 million payment tied to Rockefeller University’s licensing transaction with Gilead. With limited revenue and continuing operating losses, conventional profit margins are not meaningful.
Cash and cash equivalents were $69.3 million and marketable securities were $106.8 million at March 31, 2021, totaling $176.1 million, versus $194.4 million at December 31, 2020. Cash rose during the quarter primarily because of $44.0 million in net marketable-security sales and maturities; operating activities used $18.1 million. The filing reports no borrowings or conventional funded debt. Liabilities include lease obligations and Kolltan contingent consideration.
Total assets were $219.1 million and total liabilities were $24.9 million at quarter-end. Celldex said available cash and securities were expected to fund planned operations through 2023, while also stating in the financial-statement note that resources at filing would cover at least the next 12 months. Future milestone payments could affect liquidity.
Material changes and operating costs
- Revenue declined mainly because the $1.8 million Rockefeller transaction payment recorded in Q1 2020 did not recur; contract and grant revenue increased by $0.2 million.
- R&D expense rose by $1.0 million, led by higher product-development and clinical-trial costs. CDX-0159/anti-KIT spending increased to $6.0 million from $1.2 million; spending on CDX-1140/CDX-301 and CDX-527 declined year over year.
- Net loss increased by $3.9 million, reflecting lower licensing revenue and higher R&D costs. Loss per share was lower than in Q1 2020 despite the higher net loss; weighted-average shares rose to 39.6 million from 17.4 million, affecting comparability.
- Q1 included a $0.5 million non-cash loss from remeasurement of Kolltan contingent consideration, compared with $0.2 million in Q1 2020. Stock-based compensation increased to $1.3 million from $0.7 million.
Pipeline, outlook and risks
- CDX-0159: The company reported interim Phase 1b CIndU results: 8 of 10 patients assessed for activity had a complete response on provocation testing. The company described the candidate as generally tolerated, while reporting one severe infusion reaction. The study was expanded to include cholinergic urticaria; a prurigo nodularis study was anticipated to begin in Q4 2021, and subcutaneous formulation work was intended to support clinical introduction in Q3 2021.
- CDX-1140: The Phase 1 program includes monotherapy and combination cohorts. The recommended dose was 1.5 mg/kg; enrollment was ongoing in combinations with pembrolizumab and chemotherapy. Previously reported activity was early clinical evidence, not proof of efficacy.
- CDX-527: Phase 1 dose escalation in advanced solid tumors was ongoing.
- Management expected revenue to increase over the next 12 months as contract manufacturing and R&D services increase; product-development expense was expected to rise. It anticipated relatively consistent personnel, laboratory, facility and G&A costs, subject to quarterly fluctuations. No specific revenue, earnings or cash-flow guidance was provided.
- Celldex said COVID-19 had not significantly disrupted trials, manufacturing or shipping to date, but warned of possible impacts to enrollment, third-party services, facilities, travel and supply chains. The company has recurring losses and may seek capital through partnerships, licensing, equity, debt or business combinations; financing may be unavailable or dilutive, and inability to raise funds could force program or trial delays or discontinuations.
- The company carried $30.7 million of indefinite-lived IPR&D assets and warned that development setbacks could result in further impairment. It also disclosed an ongoing Delaware dispute with the former Kolltan stockholder representative over abandoned milestones, including whether CDX-0159 could trigger payments. Trial was scheduled for 2022; the outcome and potential exposure were not estimable. Up to $107.5 million of adjusted future Kolltan consideration remained contingent on milestones, subject to the dispute and agreement terms.
Key facts for investors to verify
- Whether CDX-0159’s interim CIndU responses persist through follow-up and are supported by larger, controlled studies, including the safety profile.
- Progress, enrollment and meaningful clinical outcomes in CDX-0159, CDX-1140 and CDX-527 trials, along with timing of the stated 2021 development plans.
- Operating cash burn, contract-service revenue and the assumptions underlying management’s funding horizon through 2023.
- Potential Kolltan milestone payments and the outcome or settlement of the SRS litigation.
- Whether COVID-19, clinical execution, manufacturing or trial results affect development timelines, costs or the carrying value of IPR&D assets.